DIAGNOS Announces a Second Contract for Its Cardio Platform with a Multinational Pharmaceutical Company and the Resignation of a Director

BROSSARD, QUEBEC--(Marketwired - Nov. 22, 2017) - DIAGNOS Inc. ("DIAGNOS", "the Corporation" or "we") (TSX VENTURE:ADK)(OTCQB:DGNOF), a leader in early detection of critical health issues through the use of its FLAIRE platform based on Artificial Intelligence (AI), announces today a second Cardio project with one of the largest pharmaceutical company in the world to monitor hypertensive patients under treatment and the resignation of Dr. Netan Choudhry, Director since 2016.